Study on Integrating the Systematic Detection of Breast Arterial Calcifications (BAC) in Routine Mammograms Within a Population-based Breast Cancer Screening Programme to Improve Cardiovascular Prevention in Women. (DUALMAMO)
Heart disease is the leading cause of death in women, yet it often goes undetected until it's too late. This project uses a simple clue found during routine breast cancer screenings-breast arterial calcification (BAC)-to spot early signs of heart risk in women aged 50 to 70. Those identified with BAC will be invited to take part in a personalized prevention program. This includes support to adopt healthier habits-like being more active, eating better, sleeping well, and managing stress-and regular checks of key health measures such as blood pressure and cholesterol. The study will compare two levels of care: a nurse-led program and a more intensive, app-supported version.
By turning mammograms into a dual-purpose tool for breast and heart health, this project empowers women with early action to reduce risk and improve long-term well-being.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Background and rationale Cardiovascular disease (CVD) is a leading cause of death in women, and cardiovascular risk is frequently underrecognized in this population. Breast arterial calcification (BAC), a form of medial vascular calcification visible on mammography, has been associated with increased cardiovascular risk. Because mammography is already performed in population-based breast cancer screening, BAC offers an opportunity to identify women who may benefit from cardiovascular prevention without additional imaging or radiation exposure. Artificial intelligence (AI) algorithms enable automated, scalable BAC detection within screening workflows.
Study design DUALMAMO combines two components: (1) AI-based detection of BAC in screening mammograms from Hostpital del Mar breast cancer screening program, and (2) a randomized controlled trial among eligible BAC-positive women, comparing a digital multicomponent lifestyle intervention with standard primary care advice. The study assesses whether this strategy improves cardiovascular risk factor control and, over longer follow-up, reduces major adverse cardiovascular events. Outcomes are detailed in the Outcome Measures section.
Procedures Women are eligible once their screening result is known. BAC-positive women are identified by the AI algorithm and invited by letter to participate through the study app/web platform. After informed consent, participants attend a baseline in-person visit (questionnaires, blood test, and clinical measurements) and are randomized through the app. A second in-person visit takes place at 6 months, with the blood test repeated if no recent result is available. Clinical events are followed up to 36 months through.
Implementation The trial also evaluates recruitment, retention, adherence, and cost-effectiveness to inform the potential integration of BAC-based cardiovascular risk identification into routine breast cancer screening.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women participating in the population-based mammography screening program in the Hospital del Mar.
- Presence of breast arterial calcification (BAC+) on the screening mammogram, as detected by the AI algorithm, ang confirmed by the Radiologists
- Access to an internet-connected device and ability to use the study app/web platform.
- Signed informed consent.
Exclusion Criteria:
- Breast cancer diagnosis or recall for additional testing following the screening mammogram.
- History of stroke, myocardial infarction, or angina pectoris.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervensjonsgruppe
|
A blood test to determine the following: -Colesterol total (mg/dL)
Cardiovascular risk factors questionnaire Patient Health Questionnaire-9 (PHQ-9) EuroQol 5-Dimension (EQ-5D) Chrononutrition Profile - Questionnaire (CP-Q) International Physical Activity Questionnaire (IPAQ) Participants receive 6 months of access to a digital platform with structured educational modules on cardiovascular risk factors (sleep, diet, cholesterol, glucose, weight, physical activity, blood pressure, smoking and environmental factors), together with a personalized physical activity program. Participants also receive their baseline laboratory results review and the same information leaflet on breast arterial calcification (BAC) provided to the usual care arm. Allocation is by random assignment through the study application. |
|
Aktiv komparator: Kontrollgruppe
|
A blood test to determine the following: -Colesterol total (mg/dL)
Cardiovascular risk factors questionnaire Patient Health Questionnaire-9 (PHQ-9) EuroQol 5-Dimension (EQ-5D) Chrononutrition Profile - Questionnaire (CP-Q) International Physical Activity Questionnaire (IPAQ) Participants receive personalized cardiovascular health advice reflecting routine primary care practice, together with written information on BAC and its cardiovascular significance. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants achieving cardiovascular risk control targets
Tidsramme: 6 months
|
LDL cholesterol <100 mg/dL, blood pressure <140/90 mmHg, and/or ≥20% reduction in cardiovascular risk |
6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in depressive symptoms
Tidsramme: 6 months
|
PHQ-9 |
6 months
|
|
Change in health-related quality of life
Tidsramme: 6 months
|
EuroQol-5 (EQ-5D) |
6 months
|
|
Change in physical activity
Tidsramme: 6 months
|
IPAQ |
6 months
|
|
Change in crononutrition profile
Tidsramme: 6 months
|
6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 2025/12505/I
- 2025 (U.S. NIH-stipend/kontrakt)
- PI25/00050 (Annet stipend/finansieringsnummer: ISCIII)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .